Researchers Developed Light-Controlled Protein Degradation
The new system, termed RuPHOTACs, enables precise spatiotemporal control over protein levels in living cells.
Updated on Sept. 30, 2026 in Biotech
Live Poll
Do you trust that new medical research breakthroughs will eventually improve standard patient care?
Scientists have introduced RuPHOTACs, a system utilizing Ruthenium-based photocages that allow for light-triggered protein degradation. This research-stage technology targets bromodomain-containing proteins and uses red light for activation.
Why it matters
Conventional PROTACs often lack the necessary precision, leading to unintended effects in non-target tissues. This light-activated approach provides the spatiotemporal control required to study protein function with higher specificity.
The system utilizes low-energy red light to release Ruthenium-based photocages that trigger interactions between E3 ubiquitin ligases—enzymes that tag proteins for destruction—and target proteins. The integration of Dendra2, a fluorescent protein reporter, allows for real-time tracking of degradation kinetics without affecting cell health.
The details
RuPHOTACs function by using a Ruthenium-based photocage, a molecular shield that is removed when exposed to specific wavelengths of light. Once released, the molecule bridges E3 ubiquitin ligases to target bromodomain-containing proteins, marking them for proteasomal degradation. By incorporating Dendra2 fusion, the team can distinguish between active degradation and the synthesis of new proteins within a living cell, providing a more granular view than traditional methods.
Timeline
September 30, 2026: Official publication of the research findings.
The Tech Race
This development addresses the primary hurdle in the field of targeted protein degradation, which is currently dominated by small-molecule inhibitors lacking precise activation timing. The research advances the capability beyond static degradation molecules by introducing light-based control as a new research standard.
This research provides a new tool for laboratories to study protein kinetics in live cells with higher precision. It is currently a research-stage technique and will require further refinement before it reaches standard experimental workflows in drug discovery.
The takeaway
This technology moves the field toward precise spatial control of proteomic manipulation. Future studies should monitor whether this light-activation system can be integrated into high-throughput screening platforms for drug development.
Further reading
For more developments in molecular tools, explore the Biotech section.
More information
Read the full Research article on RuPHOTAC protein degradation published in Nature Communications.
Source note: This article includes information reported by Nature.
Live Poll
Do you trust that new medical research breakthroughs will eventually improve standard patient care?
